NOVAVAX(#NOVAVAX) weekly uptrend special report based On 1 Lot Calculation:
GLOBAL PHARMACEUTICAL INDUSTRY:
- THE GLOBAL PHARMACEUTICAL INDUSTRY IS CURRENTLY WORTH ~$1.11T: According to the most recent reports, the Pharmaceutical industry is worth approximately $1.11T. The pharmaceutical industry is one of the largest industries in the world, which provides products that deal with infectious diseases and various illnesses.
- MARKET POTENTIAL: THE PHARMACEUTICAL INDUSTRY IS EXPECTED TO GROW TO A $2.13T DOLLAR MARKET BY 2026: Analysts are forecasting, that at the current rate of growth, the pharmaceutical industry is expected to reach $2.13trillion in value. Analysts highlight that this represents an industry compounded annual growth of 7.7% a year.
The Company -
- Novavax is a biotechnology company, it provides innovative vaccines to help deal with serious infectious diseases around the world. The company produces approximately two billion vaccine doses per day.
- NOVAVAX LEADS IN THE RACE FOR THE COVID/FLU COMBO SHOT: Of the major vaccine manufacturers, only Moderna and Novavax. Novavax has managed to submit phase 1/2 data and start phase 2 data, while Moderna still hasn’t finished enrolling people for phase 1. This gives Novavax the competitive edge for this product and expands the company’s revenue stream.
- GERMAN HEALTH AUTHORITY RECOMMENDS NOVAVAX COVID-19 VACCINE AS BOOSTER (DECEMBER 16, 2022): German Health Authorities have now approved Novavax as a booster for both ages 12-17 and 18+ in Germany. The booster is now approved in 35 countries, with multiple others in the process of approving the booster. Growth in approvals enables Novavax to expand its revenue stream globally.
- PHASE II CLINICAL TRIAL FOR NEW VACCINE UNDERWAY (DECEMBER 15, 2022): Novavax has announced that phase II clinical trials of its covid-influenza combination vaccine have begun, and confirmation of the trial results are expected by Q2 2023.
- OVER THE LAST 5 YEARS, NOVAVAX SHOWS AN AVERAGE PRICE INCREASE OF 44% OVER WINTER PERIODS: According to Bloomberg data, Novavax has historically witnessed an average price appreciation of 44% over the last five winter periods (December 21 - March 20).
DATA SOURCE: BLOOMBERG
However, please note that past performance does not guarantee future results.
- ANALYSTS OPINIONS: Jefferies has a price target of $90, Cowen Research target is $55 while JP Morgan targets $27. The Bloomberg Analyst Consensus has an average price target of $51.80.
- STOCK PRICE ACTION: THE STOCK HAS HAD A DOWNWARD CORRECTION OF AROUND 97.33% FROM IT'S RECENT HIGHS TIME HIGH OF $332.00. The stock has fallen to its lowest rate since March, 2020, to $8.85. Novavax was last trading around $11.00, and If a full recovery follows recent all- time highs, the stock could see an upside of around ~2,918%. However, the price could decline.
NOVAVAX STOCK PRICE CHART 1995 – 2022
SOURCE: BLOOMBERG
- NOVAVAX, December 19, 2022
Current Price: 11.00
|
Novavax |
Weekly |
|
Trend direction |
|
|
27.00 |
|
|
22.00 |
|
|
18.00 |
|
|
7.00 |
|
|
6.00 |
|
|
5.00 |
Example of calculation based on weekly trend direction for 1 Lot1
|
Novavax |
||||||
|
Pivot Points |
||||||
|
Profit or loss in $ |
8,000.00 |
5,500.00 |
3,500.00 |
-2,000.00 |
-2,500.00 |
-3,000.00 |
|
Profit or loss in €2 |
7,571.46 |
5,205.38 |
3,312.51 |
-1,892.86 |
-2,366.08 |
-2,839.30 |
|
Profit or loss in £2 |
6,519.97 |
4,482.48 |
2,852.49 |
-1,629.99 |
-2,037.49 |
-2,444.99 |
|
Profit or loss in C$2 |
10,930.08 |
7,514.43 |
4,781.91 |
-2,732.52 |
-3,415.65 |
-4,098.78 |
- 1.00 lot is equivalent of 500 units
- Calculations for exchange rate used as of 09:40(GMT) 19/12/2022
Fortrade recommends the use of Stop-Loss and Take-Profit, please speak to your Senior Account ManagerClient Manager regarding their use.
- You may wish to consider closing your position in profit, even if it is lower than suggested one
- Trailing stop technique can protect the profit – Ask your Senior Account ManagerClient Manager for more detail